{"success":true,"data":{"pressRelease":{"id":"144501","rtpr_id":"nGNX4VLxy0-20260915","ticker":"JSPR","exchange":"NASDAQ","all_tickers":["JSPR"],"title":"Jasper Therapeutics Announces Key Regulatory and Clinical Appointments","author":"Globe Newswire","published_at":"2026-09-15T20:05:00.154Z","article_body":"Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory\nAffairs\n\nShiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development\n\nREDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics,\nInc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company\nfocused on the design and development of innovative therapies to treat\nimmune-mediated diseases, today announced the appointments of Lisa Pitt,\nPharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang\nLiu, M.D., Ph.D. as Vice President, Clinical Development.\n\n“We are excited to have Lisa and Shiguang join us at Jasper following our\nmerger with Kira Pharmaceuticals,” said Jeet Mahal, President and Chief\nExecutive Officer of Jasper. “Lisa’s experience in regulatory affairs at\nmultiple biotech companies and the FDA, along with Shiguang’s expertise in\nclinical development in rare diseases in renal and metabolic disorders are key\nadditions as we move forward with the development of vensobafusp alfa\n(KP104), briquilimab and KP701 across a number of immune diseases.”\n\nDr. Pitt brings over 25 years of experience in leading regulatory and medical\naffairs across both the industry and at the U.S. Food and Drug Administration\n(FDA). Most recently, she served as Vice President, Regulatory Affairs at\nAiolos Bio prior to its acquisition by GlaxoSmithKline. Prior to that, she\nheld regulatory affairs leadership roles at NorthSea Therapeutics, Horizon\nTherapeutics, and Viela Bio prior to its acquisition by Horizon Therapeutics.\nDr. Pitt served as Senior Regulatory Health Project Manager at the FDA’s\nCenter for Drug Evaluation & Research in the former Division of\nGastroenterology and Inborn Errors Products, where she managed the review of\nInvestigation New Drug (IND), New Drug Application (NDA), and Biologic License\nApplication (BLA) submissions. Earlier in her career, she served in Regulatory\nAffairs roles at AstraZeneca, PAREXEL Consulting, and Novartis. She started\nher career in laboratory quality assurance roles at Alpharma and Cambridge\nBiotech. Dr. Pitt received her Pharm.D. from the University of Maryland School\nof Pharmacy, an M.S.J. from Seton Hall Law School, and a Bachelor degree in\nBiological Sciences from the University of Delaware, and completed a\npost-doctoral clinical pharmacy fellowship at Novartis.\n\nDr. Liu joins after spending over a decade of progressive leadership roles in\nresearch and development, pharmacovigilance, and clinical development at\nSanofi. Most recently, he served as Clinical Lead and Senior Clinical Research\nDirector with a focus on rare diseases in renal and metabolic disorders and\nleadership in late-stage clinical trials and regulatory submissions. Prior to\njoining the biopharmaceutical industry, Dr. Liu held several academic\nappointments, including Assistant Professor at The Kidney Institute at the\nUniversity of Kansas Medical Center, research faculty at the Duke University\nSchool of Medicine, and Visiting Fellow at the National Institute of\nEnvironmental Health Sciences (NIEHS), National Institutes of Health (NIH).\nEarlier in his career, he was an Associate Professor and Attending Physician\nat the First Affiliated Hospital of Zhengzhou University Medical School, where\nhe also completed his residency training. Dr. Liu received his M.D. from\nZhengzhou University Medical School as well as an M.S. in Medicine and a Ph.D.\nin Cell Biology from the Chinese Academy of Medical Sciences and Peking Union\nMedical College.\n\nMaterial Inducement Grants\nJasper also announced that on September 14, 2026, it granted three new\nemployees options to purchase an aggregate of 243,000 shares of voting common\nstock (the “Options”) as material inducements to each employee’s\nemployment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The\nOptions were granted pursuant to the Jasper Therapeutics, Inc. Amended and\nRestated 2022 Inducement Equity Incentive Plan, which was approved by the\ncompensation committee of Jasper’s board of directors on March 14, 2022 and\namended and restated on June 2, 2023. The exercise price of each Option is\n$0.6328. Each Option will vest over four years, with 25% of the total number\nof shares vesting on the one-year anniversary of the date of commencement of\nsuch employee’s employment with Jasper and 1/48th of the total number of\nshares subject to each Option vesting monthly thereafter, subject in each case\nto such employee’s continued service to Jasper on each vesting date.\n\nAbout Jasper\nJasper is a clinical stage biotechnology company focused on the design and\ndevelopment of innovative therapies to treat immune-mediated diseases. Jasper\nis advancing a pipeline of medicines including KP-104, briquilimab, and\nKP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has\ndemonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH)\nand is under evaluation in other high unmet need nephrology disorders.\nBriquilimab is an anti-KIT antibody which has demonstrated positive clinical\nresults both as a conditioning agent for stem cell transplant and mast cell\nmediated diseases such as chronic urticarias and allergic asthma. KP-701, a\nnovel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for\nautoantibody-mediated disorders currently advancing to the clinic.\n\nContacts:\nAlex Gray (investors)\nJasper Therapeutics\n650-549-1454 \nagray@jaspertx.com\n\nArgot Partners (investors and media)\nkira@argotpartners.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ed6e5311-feff-4502-874f-39486c6ba17a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4VLxy0-20260915","title":"Jasper Therapeutics Announces Key Regulatory and Clinical Appointments","author":"Globe Newswire","ticker":"JSPR","created":"2026-09-15T20:05:00.154Z","tickers":["JSPR"],"exchange":"NASDAQ","article_body":"Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory\nAffairs\n\nShiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development\n\nREDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics,\nInc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company\nfocused on the design and development of innovative therapies to treat\nimmune-mediated diseases, today announced the appointments of Lisa Pitt,\nPharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang\nLiu, M.D., Ph.D. as Vice President, Clinical Development.\n\n“We are excited to have Lisa and Shiguang join us at Jasper following our\nmerger with Kira Pharmaceuticals,” said Jeet Mahal, President and Chief\nExecutive Officer of Jasper. “Lisa’s experience in regulatory affairs at\nmultiple biotech companies and the FDA, along with Shiguang’s expertise in\nclinical development in rare diseases in renal and metabolic disorders are key\nadditions as we move forward with the development of vensobafusp alfa\n(KP104), briquilimab and KP701 across a number of immune diseases.”\n\nDr. Pitt brings over 25 years of experience in leading regulatory and medical\naffairs across both the industry and at the U.S. Food and Drug Administration\n(FDA). Most recently, she served as Vice President, Regulatory Affairs at\nAiolos Bio prior to its acquisition by GlaxoSmithKline. Prior to that, she\nheld regulatory affairs leadership roles at NorthSea Therapeutics, Horizon\nTherapeutics, and Viela Bio prior to its acquisition by Horizon Therapeutics.\nDr. Pitt served as Senior Regulatory Health Project Manager at the FDA’s\nCenter for Drug Evaluation & Research in the former Division of\nGastroenterology and Inborn Errors Products, where she managed the review of\nInvestigation New Drug (IND), New Drug Application (NDA), and Biologic License\nApplication (BLA) submissions. Earlier in her career, she served in Regulatory\nAffairs roles at AstraZeneca, PAREXEL Consulting, and Novartis. She started\nher career in laboratory quality assurance roles at Alpharma and Cambridge\nBiotech. Dr. Pitt received her Pharm.D. from the University of Maryland School\nof Pharmacy, an M.S.J. from Seton Hall Law School, and a Bachelor degree in\nBiological Sciences from the University of Delaware, and completed a\npost-doctoral clinical pharmacy fellowship at Novartis.\n\nDr. Liu joins after spending over a decade of progressive leadership roles in\nresearch and development, pharmacovigilance, and clinical development at\nSanofi. Most recently, he served as Clinical Lead and Senior Clinical Research\nDirector with a focus on rare diseases in renal and metabolic disorders and\nleadership in late-stage clinical trials and regulatory submissions. Prior to\njoining the biopharmaceutical industry, Dr. Liu held several academic\nappointments, including Assistant Professor at The Kidney Institute at the\nUniversity of Kansas Medical Center, research faculty at the Duke University\nSchool of Medicine, and Visiting Fellow at the National Institute of\nEnvironmental Health Sciences (NIEHS), National Institutes of Health (NIH).\nEarlier in his career, he was an Associate Professor and Attending Physician\nat the First Affiliated Hospital of Zhengzhou University Medical School, where\nhe also completed his residency training. Dr. Liu received his M.D. from\nZhengzhou University Medical School as well as an M.S. in Medicine and a Ph.D.\nin Cell Biology from the Chinese Academy of Medical Sciences and Peking Union\nMedical College.\n\nMaterial Inducement Grants\nJasper also announced that on September 14, 2026, it granted three new\nemployees options to purchase an aggregate of 243,000 shares of voting common\nstock (the “Options”) as material inducements to each employee’s\nemployment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The\nOptions were granted pursuant to the Jasper Therapeutics, Inc. Amended and\nRestated 2022 Inducement Equity Incentive Plan, which was approved by the\ncompensation committee of Jasper’s board of directors on March 14, 2022 and\namended and restated on June 2, 2023. The exercise price of each Option is\n$0.6328. Each Option will vest over four years, with 25% of the total number\nof shares vesting on the one-year anniversary of the date of commencement of\nsuch employee’s employment with Jasper and 1/48th of the total number of\nshares subject to each Option vesting monthly thereafter, subject in each case\nto such employee’s continued service to Jasper on each vesting date.\n\nAbout Jasper\nJasper is a clinical stage biotechnology company focused on the design and\ndevelopment of innovative therapies to treat immune-mediated diseases. Jasper\nis advancing a pipeline of medicines including KP-104, briquilimab, and\nKP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has\ndemonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH)\nand is under evaluation in other high unmet need nephrology disorders.\nBriquilimab is an anti-KIT antibody which has demonstrated positive clinical\nresults both as a conditioning agent for stem cell transplant and mast cell\nmediated diseases such as chronic urticarias and allergic asthma. KP-701, a\nnovel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for\nautoantibody-mediated disorders currently advancing to the clinic.\n\nContacts:\nAlex Gray (investors)\nJasper Therapeutics\n650-549-1454 \nagray@jaspertx.com\n\nArgot Partners (investors and media)\nkira@argotpartners.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ed6e5311-feff-4502-874f-39486c6ba17a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-15T20:05:00.208150648Z","server_sent_at_ms":1789502700208},"received_at":"2026-09-15T20:05:00.315Z","source_url":null},"analysis":{"id":"133340","press_release_id":"144501","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Jasper Therapeutics appointed Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President of Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President of Clinical Development — its first leadership additions following the merger with Kira Pharmaceuticals.\n\nPitt brings more than 25 years of regulatory and medical affairs experience spanning the FDA's CDER, Aiolos Bio, Horizon Therapeutics, and Viela Bio; Liu joins after over a decade at Sanofi leading late-stage clinical development in rare renal and metabolic disorders.\n\nAlongside the hires, Jasper granted the three new employees inducement options on an aggregate 243,000 shares at $0.6328 per share, vesting over four years with a 25% one-year cliff, under Nasdaq Listing Rule 5635(c)(4).\n\nThe appointments support advancement of Jasper's pipeline of vensobafusp alfa (KP104), briquilimab, and KP-701 across multiple immune-mediated diseases.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Post-merger team build-out at Jasper: experienced regulatory and clinical leads added as the vensobafusp alfa, briquilimab, and KP-701 pipeline advances."},"keyFigures":{"customDimensions":{"vesting_terms":"4 years, 25% cliff at one-year anniversary, then 1/48th monthly","option_exercise_price":0.6328,"inducement_options_granted":243000}},"quotedText":"We are excited to have Lisa and Shiguang join us at Jasper following our merger with Kira Pharmaceuticals","namedEntities":{"people":[{"name":"Lisa Pitt","role":"Senior Vice President, Regulatory Affairs (new appointment)"},{"name":"Shiguang Liu","role":"Vice President, Clinical Development (new appointment)"},{"name":"Jeet Mahal","role":"President and CEO of Jasper Therapeutics"}],"products":["vensobafusp alfa (KP104)","briquilimab","KP-701"],"companies":[{"name":"Jasper Therapeutics, Inc.","ticker":"JSPR","relationship":"filer"},{"name":"Kira Pharmaceuticals","relationship":"recent merger partner"},{"name":"Aiolos Bio","relationship":"Pitt's prior employer (acquired by GSK)"},{"name":"GlaxoSmithKline","relationship":"acquirer of Aiolos Bio"},{"name":"Sanofi","relationship":"Liu's prior employer"},{"name":"Horizon Therapeutics","relationship":"Pitt's prior employer"},{"name":"Viela Bio","relationship":"Pitt's prior employer"},{"name":"Novartis","relationship":"Pitt's prior employer"},{"name":"U.S. Food and Drug Administration (FDA)","relationship":"regulator; Pitt is a former CDER review manager"}],"dollarAmounts":[{"amount":"$0.6328","context":"exercise price of each inducement option"}]},"materialImpact":{"score":2,"reasoning":"Two senior-but-below-C-suite appointments (SVP Regulatory Affairs, VP Clinical Development) plus routine Nasdaq inducement option grants. They strengthen post-merger regulatory and clinical capabilities but are not market-moving."},"tickerRelevance":{"others":[],"primary":"JSPR"},"globalImportance":16,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","cSuiteChange":false,"eventGravity":"senior staff-level hires plus routine inducement grants","issuerAuthored":true,"dilutionMagnitude":"trivial (~243K options at $0.6328)"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Jasper Therapeutics appointed Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President of Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President of Clinical Development — its first leadership additions following the merger with Kira Pharmaceuticals.\n\nPitt brings more than 25 years of regulatory and medical affairs experience spanning the FDA's CDER, Aiolos Bio, Horizon Therapeutics, and Viela Bio; Liu joins after over a decade at Sanofi leading late-stage clinical development in rare renal and metabolic disorders.\n\nAlongside the hires, Jasper granted the three new employees inducement options on an aggregate 243,000 shares at $0.6328 per share, vesting over four years with a 25% one-year cliff, under Nasdaq Listing Rule 5635(c)(4).\n\nThe appointments support advancement of Jasper's pipeline of vensobafusp alfa (KP104), briquilimab, and KP-701 across multiple immune-mediated diseases.","key_figures":{"customDimensions":{"vesting_terms":"4 years, 25% cliff at one-year anniversary, then 1/48th monthly","option_exercise_price":0.6328,"inducement_options_granted":243000}},"named_entities":{"people":[{"name":"Lisa Pitt","role":"Senior Vice President, Regulatory Affairs (new appointment)"},{"name":"Shiguang Liu","role":"Vice President, Clinical Development (new appointment)"},{"name":"Jeet Mahal","role":"President and CEO of Jasper Therapeutics"}],"products":["vensobafusp alfa (KP104)","briquilimab","KP-701"],"companies":[{"name":"Jasper Therapeutics, Inc.","ticker":"JSPR","relationship":"filer"},{"name":"Kira Pharmaceuticals","relationship":"recent merger partner"},{"name":"Aiolos Bio","relationship":"Pitt's prior employer (acquired by GSK)"},{"name":"GlaxoSmithKline","relationship":"acquirer of Aiolos Bio"},{"name":"Sanofi","relationship":"Liu's prior employer"},{"name":"Horizon Therapeutics","relationship":"Pitt's prior employer"},{"name":"Viela Bio","relationship":"Pitt's prior employer"},{"name":"Novartis","relationship":"Pitt's prior employer"},{"name":"U.S. Food and Drug Administration (FDA)","relationship":"regulator; Pitt is a former CDER review manager"}],"dollarAmounts":[{"amount":"$0.6328","context":"exercise price of each inducement option"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-15T20:05:34.525Z","global_importance":16,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","cSuiteChange":false,"eventGravity":"senior staff-level hires plus routine inducement grants","issuerAuthored":true,"dilutionMagnitude":"trivial (~243K options at $0.6328)"}},"durationMs":34199,"modelName":"glm-5.3-flash"}}